ENDRA Life Sciences Inc. (NDRA)

The investment case here is structurally broken. Over the last eight years, the stock has erased nearly 100% of its value, driven by a brutal streak of seven out of eight years of negative annual returns, including a catastrophic collapse in 2024 where the price fell 99%. This isn't a temporary dip; it is a multi-year structural deterioration that suggests the market has permanently reassessed the business quality downward. Fundamentally, the company is hemorrhaging cash with negative free cash flow and negative operating cash flow, while posting significant losses on both assets and equity. The balance sheet shows a concerning debt-to-equity ratio of 6.8, indicating leverage that compounds the distress of a shrinking operation. There is no dividend to provide any cushion, and the lack of analyst coverage combined with a single, likely outdated, target price of $25 offers no credible validation for the current valuation. While recent price action shows a minor bounce off the lows, the underlying fundamentals remain deeply impaired, making this a clear avoid for both short-term traders and long-term investors.